Product
Treatment C
5 clinical trials
5 indications
Indication
Chronic Obstructive Pulmonary DiseaseIndication
Healthy Adult ParticipantsIndication
Healthy Control ParticipantsIndication
AbuseIndication
MedicationClinical trial
A Double-Blind, Multicentre, Randomized, Three-Period, Three-Treatment, Cross-Over Study to Evaluate the Effect of BGF MDI, BFF MDI, and Placebo MDI on Exercise Parameters in Participants With COPD (ATHLOS)Status: Recruiting, Estimated PCD: 2025-08-24
Clinical trial
A Phase 1 Study to Assess the Bioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and the Effect of Food on ALXN2050 Pharmacokinetics in Healthy Adult ParticipantsStatus: Completed, Estimated PCD: 2022-12-24
Clinical trial
A Single-center, Randomized, Open-label, Three-period Crossover Study to Investigate the Bioequivalence of Alpelisib Granule and Film-coated Tablet Formulation, and the Food Effect of Alpelisib Granule Formulation in Adult Healthy VolunteersStatus: Completed, Estimated PCD: 2022-11-09
Clinical trial
A Randomized, Single Blind, 3-Period, 3-Treatment, Single-dose, Crossover Study to Assess the Relative Bioavailability of BGF Propellant 1 and BGF Propellant 2 Compared With BGF MDI HFA in Healthy SubjectsStatus: Completed, Estimated PCD: 2021-05-17
Clinical trial
A Double-Blind, Randomized, Crossover Study to Assess the Abuse Potential of Intranasal Cebranopadol Compared to Oxycodone and Placebo in Healthy, Nondependent Recreational Opioid UsersStatus: Not yet recruiting, Estimated PCD: 2024-12-01